Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GH Research PLC Ordinary Shares
GHRS | US
20.25
USD1.44
7.66%
GHRS | US
Loading StockChartView...
About GH Research PLC Ordinary Shares
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
20.25
Open
18.85
High
20.27
Low
18.40
GH Research PLC a clinical-stage biopharmaceutical company engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-NN-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001 an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002 an intravenous mebufotenin product candidate; and GH003 an intranasal mebufotenin product candidate which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin Ireland.
View LessGHRS | US
Risk
84.1
Sharpe
1.33
Luna's Score
67/100
Recommendation
Buy
Luna says (GHRS | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
102.6%1 month
84.1%3 months
73.7%6 months
84.5%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.10
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
-11.97
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-45.53M
MarketCap
1.05B
MarketCap(USD)
1.05B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-16.20
Short ratio
35.79
Short perc.
10.82
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
9.49
Range1M
11.86
Range3M
11.89
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.17
Price X volume
5.45M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -11.97 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.10 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 73.71 | 72.80 | Par |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 1.05B | 3.66B | Emerging |
